Drug Profile
Interferon alpha-2b biosimilar - Reliance Life Sciences
Alternative Names: ReliFeronLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Reliance Life Sciences
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Condylomata acuminata; Hepatitis B; Hepatitis C; Kaposi's sarcoma; Malignant melanoma
Most Recent Events
- 30 Jul 2008 Launched for Condylomata acuminata in India (Parenteral)
- 30 Jul 2008 Launched for Hepatitis B in India (Parenteral)
- 30 Jul 2008 Launched for Hepatitis C in India (Parenteral)